A
Antonello Abbattista
Researcher at Pfizer
Publications - 34
Citations - 2212
Antonello Abbattista is an academic researcher from Pfizer. The author has contributed to research in topics: Lorlatinib & Lung cancer. The author has an hindex of 15, co-authored 31 publications receiving 1496 citations.
Papers
More filters
Journal ArticleDOI
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin Solomon,Benjamin Besse,Benjamin Besse,Todd M. Bauer,Enriqueta Felip,Ross A. Soo,D. Ross Camidge,Rita Chiari,Alessandra Bearz,Chia-Chi Lin,Shirish M. Gadgeel,Gregory J. Riely,Eng Huat Tan,Takashi Seto,Leonard P. James,Jill S. Clancy,Antonello Abbattista,Jean-Francois Martini,Joseph Chen,Gerson Peltz,Holger Thurm,Sai-Hong Ignatius Ou,Alice T. Shaw +22 more
TL;DR: Overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer and safety data for all treated patients (EXP1-6) are presented.
Journal ArticleDOI
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T. Shaw,Enriqueta Felip,Todd M. Bauer,Benjamin Besse,Benjamin Besse,Alejandro Navarro,Sophie Postel-Vinay,Sophie Postel-Vinay,Justin F. Gainor,Melissa Lynne Johnson,Jorg Dietrich,Leonard P. James,Jill S. Clancy,Joseph Chen,Jean-Francois Martini,Antonello Abbattista,Benjamin Solomon +16 more
TL;DR: In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-positive or ROS1-positive NSCLC, most of whom had CNS metastases and had previously had two or more TKI treatments fail.
Journal ArticleDOI
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T. Shaw,Benjamin Solomon,Benjamin Besse,Todd M. Bauer,Chia-Chi Lin,Ross A. Soo,Gregory J. Riely,Sai-Hong Ignatius Ou,Jill S. Clancy,Sherry Li,Antonello Abbattista,Holger Thurm,Miyako Satouchi,D. Ross Camidge,Steven Kao,Rita Chiari,Shirish M. Gadgeel,Enriqueta Felip,Jean-Francois Martini +18 more
TL;DR: Tumor genotyping for ALK mutations after failure of a second-generation TKI may identify patients who are more likely to derive clinical benefit from lorlatinib.
Journal ArticleDOI
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T. Shaw,Benjamin Solomon,Rita Chiari,Gregory J. Riely,Benjamin Besse,Benjamin Besse,Ross A. Soo,Steven Kao,Chia-Chi Lin,Todd M. Bauer,Jill S. Clancy,Holger Thurm,Jean-Francois Martini,Gerson Peltz,Antonello Abbattista,Sherry Li,Sai-Hong Ignatius Ou +16 more
TL;DR: Lorlatinib showed clinical activity in patients with advanced ROS1-positive NSCLC, including those with CNS metastases and those previously treated with crizotinib, and could represent an important next-line targeted agent.
Journal ArticleDOI
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
Ruth Plummer,Paul Lorigan,Neil Steven,Lucy Scott,Mark R. Middleton,Richard H. Wilson,Evan A. Mulligan,Nicola J. Curtin,Diane Wang,R. Dewji,Antonello Abbattista,Jorge Gallo,Hilary Calvert +12 more
TL;DR: This study showed that temozolomide (150–200 mg/m2/day) can safely be given with a PARP inhibitory dose of rucaparib, increasing progression-free survival over historical controls in metastatic melanoma patients.